Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer
Recruiting
Observational Study
Pancreatic Cancer
Intraductal Papillary Mucinous Neoplasm
High-grade Pancreatic Intraepithelial Neoplasia
PDAC - Pancreatic Ductal Adenocarcinoma
Mucinous Cystic Neoplasm
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 50 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 400,000 (estimated)
- Sponsor
- Changhai Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with early diagnosis crucial for improving survival. Due to the absence of effective screening methods, most patients are diagnosed at advanced stages. The population undergoing low-dose computed tomography (LDCT) screening significantly overlaps with those at high risk for PDAC; however, traditional imaging methods have limited sensiti…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Age 50 years and above.
2. Voluntary signing of informed consent.
3. Completion of LDCT examination.
Exclusion Criteria:
1. Previous history of pancreatic cancer.
2. Abdominal inflammation or diagnosis of acute pancreatitis within 6 months.
3. Poor image quality due to asci…
Contacts